Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder [NA]
This update notes the completion of a clinical trial examining cognitive behavioral therapy combined with drug treatment for obsessive-compu…
-
CLINICAL_TRIALS trial_result · 2014-04-22Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder [Phase 2]
A Phase 2 randomized, double-blind, placebo-controlled trial evaluating flumazenil for obsessive-compulsive disorder has been terminated. No…
-
CLINICAL_TRIALS withdrawal · 2014-03-27Clinical Trial Update: Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder [Phase 2]
A Phase 2 trial evaluating low-dose xenon for obsessive-compulsive disorder has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-03-26Clinical Trial Update: Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder [NA]
This clinical trial update reports on a completed study evaluating family-based cognitive-behavioral treatment for preschoolers with obsessi…
-
CLINICAL_TRIALS trial_result · 2014-03-14Clinical Trial Update: Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach [Phase 1]
This update reports the completion of a Phase 1 trial evaluating computer-assisted cognitive behavioral therapy for obsessive-compulsive dis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-02-19Clinical Trial Update: A Cognitive Behavioral Therapy of Primary Obsessions in Obsessive Compulsive Disorder [NA]
A completed clinical trial evaluating cognitive behavioral therapy targeting primary obsessions in obsessive-compulsive disorder.
-
CLINICAL_TRIALS trial_result · 2014-02-06Clinical Trial Update: Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder [Phase 2]
Phase 2 double-blind, placebo-controlled trial evaluating adding paliperidone to treatment-resistant obsessive-compulsive disorder. Results …
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic paroxetine hydrochloride product manufactured by NorthStar Rx LLC.
-
FDA approval · 2013-12-31FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Paroxetine hydrochloride hemihydrate from Mylan Pharmaceuticals, confirming the continued author…
-
CLINICAL_TRIALS trial_result · 2013-12-31Clinical Trial Update: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) [NA]
A completed clinical trial evaluating ziprasidone as a treatment for patients with schizophrenia who also have obsessive-compulsive disorder…
-
CLINICAL_TRIALS trial_result · 2013-12-23Clinical Trial Update: D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD [NA]
This completed clinical trial evaluated whether adding D-Cycloserine to cognitive-behavioral therapy with exposure and response prevention i…
-
FDA approval · 2013-12-19FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine submitted by Padagis US LLC (NDA 204516).
-
FDA approval · 2013-12-16FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride (generic sertraline), enabling a new generic versi…
-
CLINICAL_TRIALS trial_result · 2013-11-27Clinical Trial Update: Treatment of Obsessive-Compulsive Disorder [Phase 4]
Phase 4 clinical trial update for obsessive-compulsive disorder; the study has completed.
-
CLINICAL_TRIALS research · 2013-11-20Clinical Trial Update: Evaluating the Effects of Stress in Pregnancy
A completed clinical trial investigates how stress during pregnancy may affect major depressive disorder, panic disorder, generalized anxiet…
-
FDA approval · 2013-11-18FDA Approved: FLUVOXAMINE MALEATE — Original Application (Actavis Pharma, Inc.)
FDA approved a generic fluvoxamine maleate product (Actavis Pharma) under Original Application (ANDA). The indication is obsessive-compulsiv…
-
CLINICAL_TRIALS trial_result · 2013-11-15Clinical Trial Update: Refining the Target for Deep Brain Stimulation (DBS) in Severe, Treatment Refractory Obsessive Compulsive Disorder (OCD) [Phase 1, Phase 2]
This report covers a completed Phase 1/2 clinical trial evaluating refined deep brain stimulation targets for severe, treatment-refractory o…
-
CLINICAL_TRIALS trial_result · 2013-10-29Clinical Trial Update: Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder [Phase 2]
A Phase 2 pilot trial evaluated escitalopram for obsessive-compulsive disorder, with results posted after completion (2013).
-
CLINICAL_TRIALS withdrawal · 2013-09-30Clinical Trial Update: D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder [Phase 2]
Phase 2 study evaluating D-Cycloserine augmentation of exposure and response prevention for obsessive-compulsive disorder has been withdrawn…
-
CLINICAL_TRIALS trial_result · 2013-09-27Clinical Trial Update: Marinol in Trichotillomania or Obsessive Compulsive Disorder [Phase 2]
Phase 2 clinical trial update for Marinol in trichotillomania and obsessive-compulsive disorder has completed with results posted in 2013.
-
FDA approval · 2013-09-26FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for ZOLOFT (sertraline hydrochloride) submitted by Roerig.
-
FDA approval · 2013-06-28FDA Approved: PAROXETINE — Original Application (Padagis US LLC)
FDA approved a paroxetine product from Padagis US LLC under an original application.
-
FDA approval · 2013-05-24FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for fluvoxamine maleate.
-
CLINICAL_TRIALS research · 2013-04-24Clinical Trial Update: Electrophysiological Recording for Patients Receiving Deep Brain Stimulation Electrode for Treatment-resistant Obsessive-compulsive Disorder
This clinical trial update describes electrophysiological recording in patients with treatment-resistant obsessive-compulsive disorder who h…
-
FDA approval · 2013-04-23FDA Approved: FLUVOXAMINE MALEATE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma's original application for fluvoxamine maleate, a generic form of fluvoxamine for obsessive-compulsive disorder.